Oncobiologics (OTLK) Expected to Announce Earnings on Thursday

Oncobiologics (NASDAQ:OTLK) is expected to be releasing its Q3 2026 results before the market opens on Thursday, August 13th. Analysts expect Oncobiologics to post earnings of ($0.09) per share and revenue of $0.9670 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 8:30 AM ET.

Oncobiologics (NASDAQ:OTLK) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The business had revenue of $0.13 million for the quarter, compared to the consensus estimate of $4.39 million. On average, analysts expect Oncobiologics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Oncobiologics Stock Up 12.7%

Oncobiologics stock opened at $1.15 on Tuesday. The firm has a fifty day moving average of $1.30 and a 200-day moving average of $0.69. Oncobiologics has a 52-week low of $0.16 and a 52-week high of $3.39. The firm has a market capitalization of $170.88 million, a P/E ratio of -0.98 and a beta of 0.82.

Insiders Place Their Bets

In related news, Director Faisal Ghiath Sukhtian acquired 95,398 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was bought at an average cost of $1.05 per share, with a total value of $100,167.90. Following the acquisition, the director directly owned 220,972 shares in the company, valued at approximately $232,020.60. The trade was a 75.97% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ghiath M. Sukhtian bought 8,539,709 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was bought at an average cost of $0.59 per share, with a total value of $5,038,428.31. Following the transaction, the director directly owned 22,092,068 shares in the company, valued at approximately $13,034,320.12. The trade was a 63.01% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders purchased 8,664,107 shares of company stock valued at $5,162,666. Insiders own 1.80% of the company’s stock.

Hedge Funds Weigh In On Oncobiologics

A number of hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its position in shares of Oncobiologics by 865.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after buying an additional 21,941 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after buying an additional 44,063 shares during the last quarter. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on OTLK shares. Weiss Ratings cut shares of Oncobiologics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Ascendiant Capital Markets boosted their price objective on Oncobiologics from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Wall Street Zen upgraded Oncobiologics from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. HC Wainwright upped their target price on Oncobiologics to $1.60 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Finally, BTIG Research upgraded Oncobiologics from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Monday, July 27th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $4.65.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.